Oliver Lagore Vanvalin Investment Group’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $977K | Buy |
+14,067
| New | +$977K | 0.38% | 63 |
|
|
2024
Q4 | $2.1M | Buy |
24,420
+8,693
| +55% | +$748K | 0.54% | 38 |
|
|
2024
Q3 | $1.87M | Sell |
15,727
-694
| -4% | -$82.6K | 0.5% | 41 |
|
|
2024
Q2 | $2.34M | Buy |
16,421
+1,591
| +11% | +$227K | 0.67% | 27 |
|
|
2024
Q1 | $1.9M | Buy |
14,830
+2,739
| +23% | +$352K | 0.56% | 32 |
|
|
2023
Q4 | $1.25M | Buy |
12,091
+4,945
| +69% | +$512K | 0.47% | 36 |
|
|
2023
Q3 | $650K | Buy |
7,146
+2,856
| +67% | +$260K | 0.26% | 61 |
|
|
2023
Q2 | $347K | Buy |
4,290
+2,488
| +138% | +$201K | 0.13% | 106 |
|
|
2023
Q1 | $143K | Buy |
1,802
+1,776
| +6,831% | +$141K | 0.06% | 102 |
|
|
2022
Q4 | $1.76K | Hold |
26
| – | – | ﹤0.01% | 563 |
|
|
2022
Q3 | $1K | Buy |
+26
| New | +$1K | ﹤0.01% | 594 |
|